The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Oncologists’ preferences for first-line (1L) treatment of ALK-positive metastatic NSCLC in the US: A discrete choice experiment (DCE).
 
Kathryn Mileham
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Merck; Takeda
 
Laura Panattoni
Employment - Precision AQ
Consulting or Advisory Role - Takeda (Inst)
 
Luis Hernandez
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Grace Gahlon
Employment - Precision AQ
Consulting or Advisory Role - Takeda (Inst)
 
Pedro Labisa
Employment - Takeda
 
Nicole Bariahtaris
Employment - Precision AQ
Consulting or Advisory Role - Takeda (Inst)
 
Marlon Graf
Employment - Precision AQ
Consulting or Advisory Role - Takeda (Inst)
 
Christopher Danes
Employment - Takeda
 
Nathan Pennell
Consulting or Advisory Role - Anheart Therapeutics; bristol-myers sqibb; ConcertAI; Daiichi Sankyo; Genentech; Iovance Biotherapeutics; Janssen Oncology; Lilly; ResistanceBio; Takeda; Vial
Research Funding - Advenchen Laboratories (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); InhibRx (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Navire (Inst); Puma Biotechnology (Inst); Seattle Genetics/Astellas (Inst); Summit pharmaceuticals (Inst)